When it comes to taking control and ensuring your patients are protected against the devastating effects of stroke, your oral anticoagulant needs to have proven safety and efficacy.
Pradaxa has been studied extensively in numerous clinical trials, including the pivotal RE-LY® trial with over 18,000 patients with non-valvular atrial fibrillation.1-3
*Pradaxa 110 mg BID, indicated for certain patients, was shown to be as effective as warfarin in preventing stroke and systemic embolism.1-3 These results were shown in the RE-LY trial, which was a PROBE (prospective, randomized, open-label with blinded endpoint evaluation) trial.4
Safety and efficacy benefits of Pradaxa in patients with non-valvular atrial fibrillation
How do the safety and efficacy benefits of Pradaxa compare with warfarin?
In RE-LY, Pradaxa significantly reduced rates of stroke and systemic embolism vs warfarin (primary endpoint), as well as significantly reducing the risk of intracranial hemorrhage.†1–3
† Pradaxa 150 mg BID
SE: Systemic embolism; ICH: Intracranial hemorrhage.
RRR: Relative Risk Reduction
Choosing the right Pradaxa dose for your patients
Does the experience with Pradaxa extend to both doses?
Both the 150 mg and 110 mg BID Pradaxa doses have been extensively studied3,5,6 to ensure you have flexibility when prescribing.
Long-term Pradaxa follow up
It’s reassuring to have positive clinical trial results but how an anticoagulant works long term is also a valid concern when choosing a treatment.
RELY-ABLE® was a long-term multi-center, double-blind extension trial involving patients who received Pradaxa 150 mg or 110 mg BID during the RE-LY trial.5 With the combination of RE-LY and RELY-ABLE, Pradaxa is the only NOAC that demonstrated more than 6 years of safety and efficacy data and a benefit-risk profile you can have confidence in.1-3,7
You may also like to watch these:
- Connolly SJ et al. N Engl J Med 2009;361(12):1139–1151.
- Connolly SJ et al. N Engl J Med 2010;363(19):1875–1876 (appendix).
- Connolly SJ et al. N Engl J Med 2014;371(15): 1464–1465.
- Ezekowitz MD et al. Oral presentation #10684 on Monday 18 November 2013 at the American Heart Association Scientific Sessions, Dallas, Texas, USA.
- Paikin JS et al. Expert Rev Cardiovasc Ther 2012;10(8):965-972.
- Granger CB et al. N Engl J Med 2011;365(11):981-992.
- Connolly SJ et al. Circulation 2013;128(3):237-243.